PMVP Stock — PMV Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$1.50

Market cap

$113.3M

Cash

$79.4M

Enterprise value

$33.9M

Balance sheet

Cash	$79.4M
Debt	$0.0M
Net cash	$79.4M
Enterprise value	$33.9M
Basic shares	75.5M shares
Fully diluted shares	153.2M shares
Fully diluted market cap	$229.8M
Cash per share	$1.05

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PMVP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 26 - Mar 9	rezatapopt	Phase 1/2	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer	—
Apr 12 - May 24	metformin hydrochloride 500 mg tablet	Phase 1	TP53 Y220C Mutation; Advanced Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Rezatapopt

Phase 2 · Active Modality: small molecule (oral)

Target mutant p53 (Y220C)

Indications

ovarian cancer (platinum-resistant/refractory, TP53 Y220C) (Phase 2)
solid tumors (TP53 Y220C, tumor-agnostic) (Phase 2)

Catalysts

— first quarter of 2027

Status note Lead candidate: orally available small molecule that structurally corrects mutant p53 with the Y220C mutation. PYNNACLE Phase 1/2; single-arm Phase 2 registrational portion (dosed since Q1 2024) intended as pivotal. FDA Fast Track (October 2020) and Orphan Drug Designation (March 2026, for TP53 Y220C ovarian/fallopian tube/peritoneal cancer). Note: going-concern doubt disclosed — cash may not fund operations for one year from this report. Other p53 programs undescribed as distinct candidates.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	rezatapopt
Lead indication	Advanced Solid Tumor
Lead phase	Phase 1/2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04585750	Phase 1/2	Recruiting	Sponsor	PMV Pharmaceuticals, Inc	MRK	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer	—
NCT07372625	Phase 1	Recruiting	Sponsor	PMV Pharmaceuticals, Inc	—	TP53 Y220C Mutation; Advanced Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for PMV Pharmaceuticals, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	201,008	-30,000	0.01%	2026-08-14
Ikarian Capital	89,136	no change	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PMVP — PMV Pharmaceuticals Inc.